Although chemotherapy is considered a helpful cancer therapy, in most cases, cancer patients become resistant to chemotherapy medicines during the treatment, and therefore normal cancer cases progress to advanced stages[25]. According to the American Society of Clinical Oncology (ASCO), the 5-year survival rate of the gastric cancer patients who are diagnosed and treated before the spread of the cancer outside stomach is 69%. The percentage is 31% if the cancer spreads to the surrounding tissues or organs and/or the regional lymph nodes, and finally the rate reduces to 5% if it spreads to distant parts in the body[26] .
Improvements in the field of nanotechnology have provided a more potential strategy for resolving the above-mentioned problem and its negative consequences. Greater penetration into tissues at molecular level, improved drug localization and cellular uptake, higher feasibility to program NPs to identify cancer cells, healthy cells interaction avoidance and larger surface area are some of the properties of nanomedicines that are helpful in controlling and treating cancers[27]. Resolving the challenges of synthesizing controllable, reproducible and scalable NPs as well as improving NPs screening and evaluation will facilitate clinical development[28-30].
Nanochelating technology is a branch of nanotechnology and has recently succeeded in introducing novel nanomedicines that do not need any carriers as their new synthesis method can improve their performance. The anticancer effect of one of these nanomedicines on gastric cancer patients was evaluated in the present study.
Numerous studies have demonstrated the important role of iron in inducing oxidative damage in cancer initiation and development[31, 32]. It is well-known that neoplastic cells express high levels of transferrin receptor 1 and that cancer cells are highly in need of iron. It is also well-proven that iron metabolism is the downside of all kinds of neoplastic cells, and iron maldistribution in cancer patients[33, 34] often causes the disturbance of many physiological processes such as hemoglobin synthesis[35], and as a result of this, anemia is detected in approximately 40%-70% of all cancer patients[36, 37]. Therefore, in view of the vital role of iron in cell physiological[38] processes as well as hematopoiesis, the need for an agent that can redistribute iron well without excreting it seems essential, otherwise the anemia could be exacerbated.
In dozens of studies, the antineoplastic effects of iron chelators are evaluated in vitro, in vivo and in clinical trials. In cell culture as well as animal studies, the efficacy of several iron chelators has been already proven and the mechanisms of their antineoplastic activity (inducing cell cycle arrest, inhibition of ribonucleotide reductase, up-regulation of Ndrg1 and increase in P53 expression) are determined.
Desferrioxamine (DFO) is an FDA-approved iron chelator as the recommended first-line therapy for iron overload in patients with thalassemia major[39]. The anticancer effects of DFO are also widely evaluated in cell culture and animal models[40, 41], but due to its poor oral bioavailability and short plasma half-life, it must be administered via slow subcutaneous administration during 8-12 hours, 5-7 days/week, often resulting in poor compliance[42].
Triapine is another iron chelator that is widely evaluated in clinical trials for different neoplastic diseases, revealing that its antineoplastic effect is due to the combined action of iron chelation and free radicals generation[43-45]. A number of conducted studies on Triapine have failed to meet the minimal efficacy, while several studies have demonstrated the opposite. It should be noted that the consumption of this iron chelator in these studies caused several adverse effects such as methemoglobinemia, fatigue, nausea and vomiting.
Therefore, according to the proven role of iron in cancer initiation, development and progress, and in view of the above-mentioned studies, it seems essential to use an efficient technology to design a safer and more efficient agent that has iron chelating property and is capable of the smart management of iron redistribution without inducing the adverse effects of iron excretion, such as anemia.
In the previous study, it was revealed that BCc1 nanomedicine has iron chelating and antineoplastic properties. This nanomedicine could induce apoptosis and cell arrest in cancer cells as well as their genes expression[19]. In a cancer animal model, it was demonstrated that the mixture of BCc1 nanomedicine and doxorubicin could increase the mean OS of the cancer mice by 48%, where doxorubicin dose was reduced by 50 times[46].
In a clinical trial, the effect of BCc1 nanomedicine on metastatic and non-metastatic gastric cancer patients was evaluated for the first time. The follow-up results of consuming BCc1 after 18 and 40 months showed that the median OS of the metastatic patients who received BCc1 was 112 and 96 days more than those who took placebo, respectively. Likewise, the median OS of the non-metastatic patients in the BCc1 group was 184 and 198 days more than those in the placebo group[3].
Moreover, the analysis of the patients showed that consuming this nanomedicine, despite having iron chelating property, had no negative impact on cell blood count, ferritin, transferrin iron binding capacity and other performance characteristics of iron[3, 19]. In addition, the evaluation of a number of liver function-related characteristics and enzymes showed their normal performance in the BCc1 groups.
As a result, considering the iron chelating property of Bcc1 nanomedicine without its negative impact on important iron-related properties in the body as well as the positive impact of this nanomedicine on the OS of cancer patients, it could be claimed that BCc1 nanomedicine can inhibit cancer development by intelligently affecting iron metabolism without any adverse effect on physiological indices.
Furthermore, in the previous study, the analysis of the median OS of the patients who only used BCc1 or placebo showed that the median differences were in favor of the BCc1 groups with 121 and 12-day differences in the metastatic and non-metastatic groups, respectively. The same analysis in the present study showed that the differences increased from 121 to 128 days in the metastatic patients and from 12 to 30 days in the non-metastatic patients. These results indicate that BCc1 nanomedicine could be regarded as an independent anticancer nanomedicine deserving further investigations in the future.
Since the design of small molecules capable of targeting several pathways at the same time is a serious challenge in the field of cancer therapy, discovering the precise impacting mechanisms of BCc1 nanomedicine novel structure through further scientific and experimental researches can introduce it as an invaluable nanomedicine for controlling and treating cancer cells.